STOCK TITAN

Mineralys officer plans $209K stock option sale

An officer of Mineralys Therapeutics filed a Rule 144 notice to sell 7,438 shares via a broker-assisted cashless option exercise, following prior stock sales in recent months.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock that an officer, Eric Warren, has filed a notice to sell under Rule 144. The notice covers a proposed sale of 7,438 shares of common stock on September 21, 2026 through a broker assisted cashless exercise of employee stock options. The filing also lists several prior sales of Mineralys common stock by Warren during the preceding three months.

Positive

  • None.

Negative

  • None.
Shares to be sold 7,438 shares Proposed Rule 144 sale of Mineralys Therapeutics common stock on September 21, 2026
Aggregate market value (proposed sale) $209,135.39 Aggregate market value shown for the 7,438 shares in the Rule 144 notice
Shares outstanding 88,406,885 shares Mineralys Therapeutics common stock outstanding as listed in the securities information section
Prior sale on June 26, 2026 104,124 shares for $2,696,321.98 Common stock sale by Eric Warren during the past 3 months
Prior sale on July 21, 2026 7,438 shares for $199,884.80 Common stock sale by Eric Warren during the past 3 months
Prior sale on August 21, 2026 7,437 shares for $193,188.40 Common stock sale by Eric Warren during the past 3 months
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
broker assisted cashless exercise financial
"Broker assisted cashless exercise"
aggregate market value financial
"209135.39 | 88406885 | 09/21/2026"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Common Stock financial
"Common Stock | 09/21/2026 | Exercise of employee stock options"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Mineralys Therapeutics, Inc. (MLYS)?

The filing discloses that an officer, Eric Warren, has given notice under Rule 144 of his intent to sell 7,438 shares of Mineralys Therapeutics common stock on September 21, 2026 through a broker assisted cashless exercise of employee stock options.

How many Mineralys Therapeutics (MLYS) shares are proposed to be sold in this notice?

The notice covers a proposed sale of 7,438 shares of Mineralys Therapeutics, Inc. common stock, with the planned sale date stated as September 21, 2026 and the method described as a broker assisted cashless exercise of employee stock options.

What prior Mineralys Therapeutics (MLYS) stock sales by Eric Warren are listed?

The filing lists three prior sales: 104,124 shares on June 26, 2026 for $2,696,321.98, 7,438 shares on July 21, 2026 for $199,884.80, and 7,437 shares on August 21, 2026 for $193,188.40.

What total number of Mineralys Therapeutics (MLYS) shares does the Form 144 show as outstanding?

The Form 144 lists 88,406,885 shares of Mineralys Therapeutics, Inc. common stock as outstanding in the securities information section, alongside the proposed Rule 144 sale details.

What is the stated aggregate market value for the proposed Mineralys Therapeutics (MLYS) sale?

For the proposed sale of 7,438 shares of Mineralys Therapeutics common stock, the securities information section shows an aggregate market value of $209,135.39, in connection with the planned Rule 144 transaction dated September 21, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading